The Fundingsland Group’s Post

Concept Medical Inc is excited to Participate in a significant way at the Euro PCR -2024- one of the World- leading Courses In Interventional Cardiovascular Medicine . Come visit us to get a glimpse of the Novel US FDA breakthrough technologies that are altering standards of care & shaping percutaneous treatment futures. Concept Medical invites you to its Magic Touch Sirolimus DCB symposium .Magic Touch is the Worlds 1st CE certified and US FDA breakthrough technology backed by the largest and longest studied clinical trial program. The symposium brings together the most renowned thought leaders in the field who discuss the Novel technology , real world clinical experiences and compelling clinical trial evidence to expand indications for use in complex coronary subsets. Magic Touch , a safer Alternative in " leave nothing behind treatment paradigm" - over 180k patients treated in real world settings - Confidence Inspired by Real World Use # World's 1st CE commercialized Sirolimus DCB # World 1st Hybrid DCB+ DES technologies # Largest and Longest Studied clinical trial Program with over 23 K patients world wide # 4 US FDA Breakthrough device designations # 5 US FDA IDE approvals # 3 Late Breaking Clinical Trials

In this monthly column, Laura Dormer shares Editor’s highlights from the latest issue of the Journal of Comparative Effectiveness Research, partner journal of The Evidence Base®. Including content from Ethicon, Inc., Gilead Sciences and Optimax Access. #marketaccess #rwe #realworldevidence #rwd #realworlddata #heor #healtheconomics #outcomesresearch #valueassessment #comparativeeffectiveness

🎉 Huge congratulations to Dr. Kim Papp and the dedicated team at Alliance Clinical Trials for being one of the top enrollers (and the top enroller in Canada) for an AbbVie-sponsored #Psoriasis study! Your commitment to advancing #dermatologyresearch is truly inspiring. Keep up the amazing work! 👏 #ClinicalTrials #ClinicalResearch #PsoriasisResearch #PsoriasisAwarenessMonth #ProbityMedicalResearch

Sharing my prospective on how Quest fits in to the complex world of precision medicine.

📢 THIS WEEK! 🔗 https://bit.ly/3yi0uvH ⏰ 2:00 PM Eastern Daylight Time 🗓️ Thursday, September 5th, 2024 🎓 One (1) ARRT Category A CE Credit & One (1) AHRA CRA Credit While GBCAs are essential to performing neuro MR imaging, guidance from the US Food and Drug Administration (FDA) and the American College of Radiology (ACR) includes the recommendation of limiting a patient's gadolinium exposure One technique for reducing gadolinium exposure is to use a high-relaxivity gadolinium-based contrast agent (GBCA) that can be administered at a lower dose than a conventional GBCA without deteriorating image quality. Gadopiclenol, recently received FDA approval and is a high-relaxivity GBCA, designed to generate high-quality images at half the conventional dose of other GBCAs This educational program provides the clinical rationale for adopting the use of Gadopiclenol for neuro MRI and includes practice considerations for changing from one GBCA to another. Through case study reviews, Pareen Mehta, MD, will share clinical insights into achieving optimal image quality using a lower administered gadolinium dose when performing neuro MRI.

📚 Dive into the world of Thrombosis with the new ESC Textbook on Thrombosis! 🩸 Embark on a journey through the latest insights and expertise in thrombosis with our brand new textbook! 🌟 Authored by world renowned experts in the field, this comprehensive textbook offers a thorough exploration of all aspects of thrombosis and antithrombotic therapies. 💡 Curious to learn more? Start with a FREE chapter and secure your copy today! 📖 https://bit.ly/3UMUzaA #Thrombosis #ExpertInsights #OrderNow 📚🔍

Engage in the ultimate debate as we navigate advances in pharmacokinetics and anti-VEGF therapy. The co-developed symposium, Eyes Forward, will be taking place on Saturday, June 1 at the 2024 COS Annual Meeting and Exhibition, in Toronto, Ontario. After this session, participants will be able to: - Examine the pharmacokinetic properties of anti-VEGF agents and their role in the management of retinal diseases, including AMD, DME, and RVO; - Analyze real-world case scenarios to develop evidence-based treatment approaches for patients with diverse retinal conditions, considering the latest advancements in anti-VEGF therapy; - Explore the scientific rationale behind treatment modalities aiming to optimize treatment regimens and improve long-term visual outcomes. To learn more or join us this May 30 - June 2 in Toronto, visit cos-sco.ca/COS2024. This symposium was co-developed by the Canadian Ophthalmological Society and Bayer Inc. and was planned to achieve scientific integrity, objectivity and balance. This symposium is an accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada and approved by the Canadian Ophthalmological Society. You may claim a maximum of 1.5 hours.

The 2024 OTC Technology Showcase will be held at Nationwide Children's Hospital Conference Center on March 7th at 1 p.m. Register here for in-person or virtual attendance and join us: https://bit.ly/42U76Lw Six presenters will showcase their innovative research and emerging projects stemming from the Abigail Wexner Research Institute. Presenters affiliated with Nationwide Children’s Hospital will delve into their research and pioneering initiatives as part of the showcase. Afterward, a panel of industry experts will discuss trends and opportunities in pediatric medical device development. Aaron J. Trask, PhD, FAHA, FCVS, is a leading researcher in cardiovascular science and uses modern methods to study blood flow patterns. He focuses on how these patterns can give early clues about various diseases, specifically in small blood vessels. In his presentation, he will talk about the intersection of machine learning and cardiovascular health, shedding light on how innovative approaches can provide early indications of diseases. “Machine learning of blood flow patterns has a lot of potential to be an additional tool in a physician’s toolbelt to either diagnose or prognosticate the development of diseases.” Dr. Trask sees research through a lens of curiosity, encouraging innovators to synergize with others’ expertise and “think outside of the box.” “I always tell people that, as researchers, we’re standing on the edge of knowledge, and we’re looking over into the abyss of things we don’t know about yet. Innovative discoveries are made when you take something that’s known along with something else that’s known, and you put those things together.” Visit here for more information about the Technology Showcase, including agenda and parking details: https://bit.ly/49vFdMf #LifeAtNCH #InnovateWithUs #Investing #Pharmaceuticals #Therapeutics #MedDevices

👉 Meet us live at the #DGK Annual Meeting! Our CCO Harald Kuhlmann will be attending the DGK - German Society of Cardiology Annual Meeting #DGK2024 at the Rosengarten in Mannheim this week, from today to Friday April 5th, 2024. Harald is eager for engaging discussions, in-person meetings, and experiencing the dynamic interfaces of medical and economic realms in #Cardiology. This year's theme, "Interfaces of Cardiovascular Medicine," delves not only into interdisciplinary aspects but should also explore the interface between medicine and economics, e.g. in terms of Market Access and Reimbursement. #Cardiology thrives on innovcation! Whether in the #pharmaceutical, #MedicalDevice or #diagnostics industry, every year many companies with great new products are looking for market entry and commercial success in Europe. From the intricate workings of the heart to navigating complex market landscapes, there's a synergy that drives progress and success. inspiring-health GmbH understands the importance of navigating these intersections. We help manufacturers chart their course through the complexities of #MarketAccess & #reimbursement in #Germany and across #Europe, offering strategic insights, guidance, and support. Join us for a conversation at the conference! We're excited to exchange ideas and explore the possibilities together. Connect with Harald Kuhlmann and let's embark on this journey towards innovation and success! #Inspiring_Health #DGK #DGKAnnualMeeting Image source: Shutterstock / Leonid Andronov

From protocol development to timely recruitment and retention to regulatory approval, it is crucial that trial subjects feel involved, retain their autonomy, and understand the basics of what the trial is trying to achieve. With these thoughts in mind as we approach the 2024 ACC Scientific Sessions, we interviewed several key opinion leaders on how these principles may weave into some of the major late-breaking science that came out of last year’s AHA Scientific Sessions. Tap into these #cardiovascular insights in our latest blog from Dr Aung Myat MD FACC FESC: https://lnkd.in/gyjabQDT